# Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants

> **NCT05813314** · PHASE1 · TERMINATED · sponsor: **BioMarin Pharmaceutical** · enrollment: 36 (actual)

## Conditions studied

- Achondroplasia

## Interventions

- **COMBINATION_PRODUCT:** BMN 111 administration via Injector Pen
- **DRUG:** BMN 111 administration via vial and syringe

## Key facts

- **NCT ID:** NCT05813314
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-15
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** The BMN 111-104 study has terminated as further optimization of the approach to achieve bio equivalence is required. The study termination was not due to any patient safety concerns.
- **Last updated:** 2023-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05813314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05813314, "Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05813314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*